Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study on Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

NCT05789667 is registered in ClinicalTrials.gov with Regina Elena Cancer Institute as lead sponsor.

NCT NCT05789667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05789667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study on Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
Lead sponsor
Regina Elena Cancer Institute
Phase
Observational
Overall status
Completed
Start date
May 27, 2020
Completion date
March 31, 2025
Enrollment
138 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid cancer, gender